Studying biologic features in adults with newly diagnosed ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary ITP (ITP caused by your immune system), not secondary ITP from another disease
- You are starting first-time (first-line) ITP treatment, based on ITP guidelines
- If you started urgent treatment for dangerous bleeding already, they must collect samples within 24 hours
- You are 18 years or older
- You can sign a consent form to join the study
- Not sure/important to note: people with “triple positive” antiphospholipid antibodies are not eligible
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
This study helps doctors better understand immune thrombocytopenia (ITP) by collecting basic patient information and, if you agree, storing blood samples. It may help future care decisions and research for people with ITP.
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
This study looks at how people with immune thrombocytopenia (ITP) are treated in real life. It aims to understand which treatments work best for patients who have had ITP for up to 12 months.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.